Verona Pharma (VRNA) PT Raised to $57 at Truist Securities as Ohtuvayre Sales Exceed Expectations
Tweet Send to a Friend
Truist Securities analyst Joon Lee raised the price target on Verona Pharma (NASDAQ: VRNA) to $57.00 (from $44.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
